vs
Regions Financial Corporation（RF）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Regions Financial Corporation的季度营收约是Revvity的1.7倍（$1.3B vs $772.1M），Regions Financial Corporation净利率更高（41.7% vs 12.7%，领先28.9%），Revvity同比增速更快（5.9% vs 4.1%），过去两年Revvity的营收复合增速更高（9.0% vs 4.0%）
Regions Financial Corporation是美国银行控股企业，总部位于阿拉巴马州伯明翰市。公司提供零售及商业银行、信托、股票经纪、抵押贷款等服务，旗下银行业务子公司Regions Bank在美国南部和中西部15个州运营约1300家营业网点和2000台自动柜员机，服务大量当地个人及企业客户。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
RF vs RVTY — 直观对比
营收规模更大
RF
是对方的1.7倍
$772.1M
营收增速更快
RVTY
高出1.7%
4.1%
净利率更高
RF
高出28.9%
12.7%
两年增速更快
RVTY
近两年复合增速
4.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $534.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 55.3% | 14.5% |
| 净利率 | 41.7% | 12.7% |
| 营收同比 | 4.1% | 5.9% |
| 净利润同比 | 0.0% | 3.9% |
| 每股收益（稀释后） | $0.59 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RFRVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.3B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.2B | $684.0M | ||
| Q2 24 | $1.2B | $691.7M | ||
| Q1 24 | $1.2B | $649.9M |
净利润RFRVTY
| Q4 25 | $534.0M | $98.4M | ||
| Q3 25 | $569.0M | $46.7M | ||
| Q2 25 | $563.0M | $53.9M | ||
| Q1 25 | $490.0M | $42.2M | ||
| Q4 24 | $534.0M | $94.6M | ||
| Q3 24 | $490.0M | $94.4M | ||
| Q2 24 | $501.0M | $55.4M | ||
| Q1 24 | $368.0M | $26.0M |
毛利率RFRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率RFRVTY
| Q4 25 | 55.3% | 14.5% | ||
| Q3 25 | 56.3% | 11.7% | ||
| Q2 25 | 56.1% | 12.6% | ||
| Q1 25 | 52.0% | 10.9% | ||
| Q4 24 | 53.4% | 16.3% | ||
| Q3 24 | 49.9% | 14.3% | ||
| Q2 24 | 52.7% | 12.4% | ||
| Q1 24 | 39.2% | 6.8% |
净利率RFRVTY
| Q4 25 | 41.7% | 12.7% | ||
| Q3 25 | 45.3% | 6.7% | ||
| Q2 25 | 44.7% | 7.5% | ||
| Q1 25 | 41.0% | 6.4% | ||
| Q4 24 | 43.4% | 13.0% | ||
| Q3 24 | 40.2% | 13.8% | ||
| Q2 24 | 42.2% | 8.0% | ||
| Q1 24 | 31.1% | 4.0% |
每股收益（稀释后）RFRVTY
| Q4 25 | $0.59 | $0.86 | ||
| Q3 25 | $0.61 | $0.40 | ||
| Q2 25 | $0.59 | $0.46 | ||
| Q1 25 | $0.51 | $0.35 | ||
| Q4 24 | $0.55 | $0.77 | ||
| Q3 24 | $0.49 | $0.77 | ||
| Q2 24 | $0.52 | $0.45 | ||
| Q1 24 | $0.37 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $4.1B | — |
| 股东权益账面价值 | $19.0B | $7.3B |
| 总资产 | $158.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.22× | — |
8季度趋势，按日历期对齐
现金及短期投资RFRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务RFRVTY
| Q4 25 | $4.1B | — | ||
| Q3 25 | $4.8B | — | ||
| Q2 25 | $5.3B | — | ||
| Q1 25 | $6.0B | — | ||
| Q4 24 | $6.0B | — | ||
| Q3 24 | $6.0B | — | ||
| Q2 24 | $5.1B | — | ||
| Q1 24 | $3.3B | — |
股东权益RFRVTY
| Q4 25 | $19.0B | $7.3B | ||
| Q3 25 | $19.0B | $7.4B | ||
| Q2 25 | $18.7B | $7.6B | ||
| Q1 25 | $18.5B | $7.6B | ||
| Q4 24 | $17.9B | $7.7B | ||
| Q3 24 | $18.7B | $7.9B | ||
| Q2 24 | $17.2B | $7.9B | ||
| Q1 24 | $17.0B | $7.8B |
总资产RFRVTY
| Q4 25 | $158.8B | $12.2B | ||
| Q3 25 | $159.9B | $12.1B | ||
| Q2 25 | $159.2B | $12.4B | ||
| Q1 25 | $159.8B | $12.4B | ||
| Q4 24 | $157.3B | $12.4B | ||
| Q3 24 | $157.4B | $12.8B | ||
| Q2 24 | $154.1B | $13.4B | ||
| Q1 24 | $154.9B | $13.4B |
负债/权益比RFRVTY
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.25× | — | ||
| Q2 25 | 0.28× | — | ||
| Q1 25 | 0.32× | — | ||
| Q4 24 | 0.34× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.30× | — | ||
| Q1 24 | 0.20× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-319.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | -0.60× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流RFRVTY
| Q4 25 | $-319.0M | $182.0M | ||
| Q3 25 | $861.0M | $138.5M | ||
| Q2 25 | $573.0M | $134.3M | ||
| Q1 25 | $1.1B | $128.2M | ||
| Q4 24 | $-220.0M | $174.2M | ||
| Q3 24 | $1.3B | $147.9M | ||
| Q2 24 | $161.0M | $158.6M | ||
| Q1 24 | $396.0M | $147.6M |
自由现金流RFRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率RFRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度RFRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率RFRVTY
| Q4 25 | -0.60× | 1.85× | ||
| Q3 25 | 1.51× | 2.97× | ||
| Q2 25 | 1.02× | 2.49× | ||
| Q1 25 | 2.18× | 3.03× | ||
| Q4 24 | -0.41× | 1.84× | ||
| Q3 24 | 2.57× | 1.57× | ||
| Q2 24 | 0.32× | 2.87× | ||
| Q1 24 | 1.08× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RF
| Consumer Bank | $747.0M | 58% |
| Corporate Bank | $487.0M | 38% |
| Wealth Management | $47.0M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
